Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accounts Payables (2024 - 2025)

Prelude Therapeutics' Accounts Payables history spans 2 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 48.49% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 48.49%, while the annual FY2025 figure was $4.0 million, 48.49% down from the prior year.
  • Accounts Payables for Q4 2025 was $4.0 million at Prelude Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.7 million in Q4 2024 and bottomed at $2.5 million in Q3 2025.